Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy targets genetic weakness in Hard-to-Treat leukemia

NCT ID NCT02677922

Ongoing Disease control Sponsor: Celgene Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests two experimental drugs (AG-120 and AG-221) that target specific genetic mutations (IDH1 or IDH2) found in some acute myeloid leukemia (AML) patients. Each drug is combined with a standard chemotherapy (azacitidine) and compared to azacitidine alone. The trial enrolls 130 newly diagnosed AML patients who cannot tolerate intensive chemotherapy. The goal is to find the safest and most effective dose and see if the combinations improve response rates.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

AG-120 (ivosidenib) or AG-221 (enasidenib) plus azacitidine

What this could lead to

If successful, this could provide a more effective, less intensive treatment option for older or frail patients with a specific genetic subtype of AML.

What could go wrong

This is an early-phase trial (1b/2) with a small number of participants, so results may not confirm benefit. Side effects from the drug combinations could be serious.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEUKEMIA, MYELOID, ACUTE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LEUKEMIA, MYELOID, ACUTE

Contacts and locations

Locations

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, 02115, United States

  • Local Institution - 102

    Boston, Massachusetts, 02114, United States

  • Local Institution - 103

    Chicago, Illinois, 60637, United States

  • Local Institution - 105

    Duarte, California, 91010-301, United States

  • Local Institution - 106

    New York, New York, 10065, United States

  • Local Institution - 107

    New Haven, Connecticut, 06510, United States

  • Local Institution - 108

    Chicago, Illinois, 60611, United States

  • Local Institution - 110

    Dallas, Texas, 75390-85520, United States

  • Local Institution - 125

    Toronto, Ontario, M5G 2M9, Canada

  • Local Institution - 175

    Melbourne, 3141, Australia

  • Local Institution - 177

    Perth, 6000, Australia

  • Local Institution - 178

    Adelaide, South Australia, SA 5000, Australia

  • Local Institution - 200

    Paris, 75475, France

  • Local Institution - 201

    Villejuif, 94805, France

  • Local Institution - 202

    Pierre-Bénite, 69495, France

  • Local Institution - 203

    Toulouse, 31059, France

  • Local Institution - 204

    Pessac, 33604, France

  • Local Institution - 205

    Lille, 59037, France

  • Local Institution - 206

    Marseille, 13273, France

  • Local Institution - 225

    Ulm, 89081, Germany

  • Local Institution - 227

    Berlin, 12200, Germany

  • Local Institution - 230

    Dresden, 01307, Germany

  • Local Institution - 250

    Pesaro, 31122, Italy

  • Local Institution - 251

    Orbassano, 10043, Italy

  • Local Institution - 252

    Florence, 50134, Italy

  • Local Institution - 253

    Bologna, Emilia-Romagna, 40138, Italy

  • Local Institution - 254

    Padova, 35128, Italy

  • Local Institution - 255

    Roma, 00189, Italy

  • Local Institution - 256

    Genova, 16132, Italy

  • Local Institution - 277

    Utrecht, 3584 CX, Netherlands

  • Local Institution - 327

    Lisbon, 1169-050, Portugal

  • Local Institution - 350

    Seoul, 138-736, South Korea

  • Local Institution - 351

    Seoul, 135-710, South Korea

  • Local Institution - 375

    Barcelona, 08907, Spain

  • Local Institution - 376

    Cáceres, 10005, Spain

  • Local Institution - 377

    Valencia, 46009, Spain

  • Local Institution - 378

    Madrid, 28007, Spain

  • Local Institution - 379

    Barcelona, 08036, Spain

  • Local Institution - 380

    Málaga, 29010, Spain

  • Local Institution - 381

    Madrid, 28033, Spain

  • Local Institution - 401

    Zurich, 0, Switzerland

  • Local Institution - 403

    Basel, 4031, Switzerland

  • Local Institution - 427

    Headington, OX3 9DU, United Kingdom

  • Local Institution - 428

    London, SE5 9RS, United Kingdom

  • Local Institution - 429

    Birmingham, B15 2TH, United Kingdom

  • Local Institution - 430

    Sutton (Surrey), SM2 5PT, United Kingdom

  • Local Institution - 902

    Boston, Massachusetts, 02115, United States

  • Local Institution - UNK-121

    Yvoir, 5530, Belgium

  • Local Institution - UNK-52

    Gothenburg, 413 45, Sweden